Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

utcome measures the low-dose group showed a demonstrable, but more modest treatment effect than the high-dose group. Regarding safety, low-dose pirfenidone was also safe and generally well tolerated with overall fewer side effects than the high-dose group.

Steve Porter, M.D., Ph.D., Chief Medical Officer of InterMune, said, "While the primary endpoint was met in just one of two CAPACITY studies, there are significant consistencies across the two studies in the overall treatment effect of pirfenidone on lung function and exercise tolerance. In addition, the Study Week 48 results from both CAPACITY studies are consistent with those of the primary efficacy endpoint, change in Vital Capacity at Week 52, in the Shionogi Phase 3 study. Considering the favorable safety profile of pirfenidone and the lack of any approved treatment options for IPF patients, we believe the collective data suggest pirfenidone may play a meaningful role in the management of patients suffering from this devastating disease."

Dr. Porter continued, "We are greatly indebted to the many patients, health care providers and study personnel who dedicated themselves to the successful conduct of the CAPACITY program and enabled us to deliver high quality data."

About CAPACITY and RECAP

The CAPACITY program consisted of two multinational, randomized, double-blind, placebo-controlled Phase 3 trials, named CAPACITY 1 and CAPACITY 2, designed to evaluate the safety and efficacy of pirfenidone in IPF patients with mild to moderate impairment in lung function. The primary endpoint of both trials was change in percent predicted Forced Vital Capacity (FVC) after 72 weeks of treatment evaluated with a nonparametric rank ANCOVA analysis. Both trials enrolled patients in North America, Europe and Australia with roughly 75% of the total 779 patients enrolled in North America.

CAPACITY 1 enrolled a total of 344 patients. Pati
'/>"/>

SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)... Naurex Inc., a biopharmaceutical company leveraging its ... the central nervous system, today announced that Norbert ... present at the 33 rd annual J.P. Morgan ... 3:00 p.m. PST on Tuesday, January 13, 2015, at ... Calif. About Naurex Inc. ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Funds ... ... (PHRI) has received $2.8 million in research funding from the National Cancer Institute (NCI) to ... Hawaii, for two more years. , , , , ,Since 2002, PHRI has participated in ...
... WILMINGTON, Delaware, September 1 According to a ... ( http://www.marketsandmarkets.com ), the total global,biomaterials market is expected ... CAGR of 15.0% from 2009 to 2014. The U.S. ... total revenues. The biomaterials market today has,already crossed $28 ...
... ... of Cleveland, now offers reverse total shoulder replacement surgery. This innovative procedure relieves pain ... individuals -- who are not candidates for traditional shoulder replacement -- had been told ... ...
Cached Biology Technology:Pacific Health Research Institute Awarded $2.8 Million in Research Funding 2Pacific Health Research Institute Awarded $2.8 Million in Research Funding 3Global Biomaterials Market Worth US$58.1 Billion by 2014 2Global Biomaterials Market Worth US$58.1 Billion by 2014 3Robert Zanotti, MD, Is First Lorain County, Ohio Orthopedic Surgeon to Perform Reverse Total Shoulder Replacement 2Robert Zanotti, MD, Is First Lorain County, Ohio Orthopedic Surgeon to Perform Reverse Total Shoulder Replacement 3Robert Zanotti, MD, Is First Lorain County, Ohio Orthopedic Surgeon to Perform Reverse Total Shoulder Replacement 4
(Date:12/5/2014)... , Dec. 4, 2014 Increased ... boosted investments in new testing and inspection technologies. ... given rise to a range of innovative test ... requirements of Generation Y, which is generally more ... a result, product development strategies of test equipment ...
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... SE, Harvard University, the Massachusetts Institute of Technology (MIT), ... a research initiative called the "North American Center for ... this initiative is to jointly develop new materials for ... cooperation is initially planned for five years, during which ...
... WINSTON-SALEM, N.C. , March 11, 2013  Wake ... developments related to its commercialization enterprise, Wake Forest ... Piedmont Triad Research Park.   Wake Forest ... and beyond the community and an analysis of ...
... the microbiology field has challenged all previous knowledge of ... out studying this phenomenon, suggesting that there is a ... Northeastern University Distinguished Professor in the Department of Biology ... standard thinking at the time was that the three ...
Cached Biology News:Renewed Harvard-BASF initiative to advance functional materials 2Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 2Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 3Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 4Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 5Study: Antibiotics are unique assassins 2
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
Mouse monoclonal antibody to Lats2....
Goat polyclonal to Lipocalin 2...
Biology Products: